Technical Description
The invention involves a nuclease-resistant gene silencing agent, a modified oligonucleotide that targets mRNA via RNA interference, demonstrating high serum stability and cytotoxicity against cancer cell lines.
Problems Addressed
- Complex Process
- Topical Enzymatic Activity
- Limited Biocompatibility
- Adverse Clinical Effect
Tech Features
- Gene Modulation
- RNA Interference
- Nuclease Resistant
- Serum Stability
- Enhanced Efficiency
- Improved Cytotoxicity
Target Audience
- Pharmaceutical Industry
- Hospitals
- Oncology Clinics
- Research Institutes
Tech ID: P35-2278 TRL 5 Patent Status: Published Available For Exclusive and Non-exclusive License
